The U.S. District Judge presiding over Valsartan litigation has scheduled a meeting on June 26, with lawyers involved in federal Valsartan recall lawsuits. During this meeting, parties are expected to discuss procedures designed to advance claims brought by individuals nationwide who received versions of the blood pressure drug that were contaminated with cancer-causing chemicals.
Currently, there are five dozen product liability lawsuits pending in the federal court system against various generic drug manufacturers, each raising similar claims that generic valsartan pills were distributed for years with cancer-causing impurities, including NDMA and NDEA, which appear to be a by-product of the drug manufacturing process.
On June 24, defendants and plaintiffs filed statement outlining the proposed agenda items of the upcoming conference. According to plaintiffs’ statement, it indicated that the proposed plaintiffs’ fact sheet form submitted by defendants would be overly burdensome, and the issue is expected to be a significant part of this conference. The defendants’ statement indicated that they hope to iron out disagreements and finalize the standardized fact sheets before the July 24 conference, which will help facilitate the exchange of information about each of the valsartan recall claims.
